首页> 外文OA文献 >SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients
【2h】

SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients

机译:肾脏替代疗法中的抗生素治疗(smaRRT):重症患者的观察性药代动力学研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Optimal antibiotic dosing is key to maximising patient survival, and minimising the emergence of bacterial resistance. Evidence-based antibiotic dosing guidelines for critically ill patients receiving RRT are currently not available, as RRT techniques and settings vary greatly between ICUs and even individual patients. We aim to develop a robust, evidence-based antibiotic dosing guideline for critically ill patients receiving various forms of RRT. We further aim to observe whether therapeutic antibiotic concentrations are associated with reduced 28-day mortality. Methods/Design: We designed a multi-national, observational pharmacokinetic study in critically ill patients requiring RRT. The study antibiotics will be vancomycin, linezolid, piperacillin/tazobactam and meropenem. Pharmacokinetic sampling of each patient's blood, RRT effluent and urine will take place during two separate dosing intervals. In addition, a comprehensive data set, which includes the patients' demographic and clinical parameters, as well as modality, technique and settings of RRT, will be collected. Pharmacokinetic data will be analysed using a population pharmacokinetic approach to identify covariates associated with changes in pharmacokinetic parameters in critically ill patients with AKI who are undergoing RRT for the five commonly prescribed antibiotics. Discussion: Using the comprehensive data set collected, the pharmacokinetic profile of the five antibiotics will be constructed, including identification of RRT and other factors indicative of the need for altered antibiotic dosing requirements. This will enable us to develop a dosing guideline for each individual antibiotic that is likely to be relevant to any critically ill patient with acute kidney injury receiving any of the included forms of RRT. Trial registration: Australian New Zealand Clinical Trial Registry ( ACTRN12613000241730 ) registered 28 February 2013.
机译:背景:最佳抗生素剂量是最大化患者生存率并最大程度减少细菌耐药性出现的关键。目前尚无针对重症患者接受RRT的循证抗生素剂量指南,因为ICU甚至个别患者的RRT技术和设置差异很大。我们旨在为接受各种形式的RRT的重症患者制定可靠的循证抗生素剂量指南。我们进一步旨在观察治疗性抗生素浓度是否与降低的28天死亡率相关。方法/设计:我们针对需要RRT的重症患者设计了一项多国观察性药代动力学研究。研究抗生素为万古霉素,利奈唑胺,哌拉西林/他唑巴坦和美罗培南。每个病人的血液,RRT流出物和尿液的药代动力学采样将在两个单独的给药间隔内进行。此外,还将收集包括患者的人口统计学和临床​​参数以及RRT的方式,技术和设置在内的综合数据集。将使用群体药代动力学方法对药代动力学数据进行分析,以确定与正在接受5种常用处方抗生素的RRT的重症AKI患者的药代动力学参数变化相关的协变量。讨论:使用收集到的综合数据集,将构建五种抗生素的药代动力学概况,包括鉴定RRT和其他指示需要改变抗生素剂量要求的因素。这将使我们能够为每种单独的抗生素制定剂量指南,该指南可能与接受任何包括在内的RRT形式的任何急性肾损伤重症患者有关。试用注册:2013年2月28日注册的澳大利亚新西兰临床试验注册中心(ACTRN12613000241730)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号